Category: Include on Menu
-
Med-X targets global pest control market with Nature-Cide
Med-X CEO Matthew Mills discusses Nature-Cide, pest control partnerships, global expansion and the company’s planned Nasdaq listing.
-
Micron shares fall 1.8% following Taiwan incentive pay report
Micron Technology (NASDAQ:MU) shares fell 1.8% in pre-market trading on Tuesday following a report concerning employee incentive payments at the company’s Taiwan operations, while technology stocks also faced broader pressure from higher interest rates. Taiwan’s Liberty Times reported that Micron plans to introduce its highest incentive payment package to date for employees in Taiwan amid…
-
QC Ware and IonQ demonstrate hybrid quantum-classical chemistry workflow
QC Ware and IonQ (NYSE:IONQ) announced a technology demonstration of a hybrid quantum-classical chemistry workflow combining QC Ware’s Promethium platform with IonQ’s Forte trapped-ion quantum computer, accessed through Amazon Braket. The demonstration modelled the heme active site of cytochrome P450nor, an enzyme in the cytochrome P450 superfamily involved in nitric oxide reduction. Members of the…
-
Alumis Phase 2b lupus trial misses primary and secondary endpoints
Alumis Inc. (Nasdaq: ALMS) said its Phase 2b LUMUS trial evaluating envudeucitinib in patients with moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary or secondary endpoints in the overall study population. The trial enrolled 408 patients who received one of three doses of envudeucitinib or placebo over 48 weeks. The primary endpoint assessed…
-
Comstock Resources shares rise 5% after $1.65 billion SOCAR agreement and $450 million drilling venture
Comstock Resources (NYSE:CRK) shares rose 5% on Tuesday after the company announced a letter of intent with the State Oil Company of the Azerbaijan Republic (SOCAR) covering a proposed $1.65 billion asset transaction, alongside a separate drilling venture involving approximately $450 million of expected costs with a partnership owned by the family of majority stockholder…
-
Stoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congress
Stoke Therapeutics (NASDAQ:STOK) and Biogen (NASDAQ:BIIB) said they will present clinical data for zorevunersen, their investigational treatment for Dravet syndrome, at the 16th European Epilepsy Congress in Athens, Greece, from September 5 to 9. The presentations will include the first disclosure at a medical meeting of four-year results from ongoing Phase 1/2a open-label extension studies.…
-
Fervo Energy shares rise 15% following Google geothermal power agreement
Fervo Energy (NASDAQ:FRVO) shares rose 15% on Tuesday morning following a Wall Street Journal report that the geothermal company had secured its largest power agreement to date with Alphabet’s Google (NASDAQ:GOOG). The agreement covers nearly 400 megawatts of electricity from Fervo’s Cape Station project in southwestern Utah. Fervo plans to begin supplying electricity to Google…
-
Medtronic shares rise 5% after earnings beat and guidance increase
Medtronic plc (NYSE:MDT) shares rose 5% after the medical device company reported first-quarter fiscal 2027 results above analyst expectations and increased its full-year revenue growth and earnings guidance. Adjusted earnings per share came in at $1.45, exceeding the consensus estimate of $1.39 by $0.06. Revenue increased 13.7% year over year to $9.8 billion, compared with…
-
Keurig Dr Pepper to sell Chobani stake and facility for $925 million
Keurig Dr Pepper (NASDAQ:KDP) said on Tuesday that it will sell its investment in Chobani back to the yogurt maker for a total of $925 million as the beverage company continues to reshape its portfolio following its acquisition of JDE Peet’s. Under the transaction, Keurig Dr Pepper will sell its entire equity interest in Chobani…
-
Tempus AI shares rise 2.7% following analyst actions
Tempus AI (NASDAQ:TEM) shares rose 2.7% in pre-market trading following analyst actions from Piper Sandler and Canaccord Genuity as investors assessed the company’s pending acquisition of Personalis. Piper Sandler upgraded Tempus AI to “Overweight” from “Neutral” and increased its price target to $76 from $56. The brokerage cited three factors in its assessment: Personalis’ tumor-informed…